Tokyo, Japan

Ayano Suzuki

This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Daicel Corporation. Active years: 2024-2026.

USPTO Granted Patents = 2 

% Patents Active = 50.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2024-2026

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ayano Suzuki: Innovator in Biomolecular Injection Technology

Introduction

Ayano Suzuki is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of biomolecular technology, particularly in the development of innovative injection methods. Her work focuses on enhancing the efficiency of biomolecule delivery systems.

Latest Patents

Ayano Suzuki holds a patent for an "Injector and method of injecting solution containing biomolecules into injection target using the same." This invention relates to an injector designed to maximize the proportion of biomolecules that effectively function within the injection target. The injector allows for the injection of a solution containing biomolecules without the need for a specific structure to be inserted into the target, thereby improving the delivery process.

Career Highlights

Ayano Suzuki is currently employed at Daicel Corporation, where she continues to innovate in the field of biomolecular applications. Her work has garnered attention for its potential to improve medical and scientific practices related to biomolecule delivery.

Collaborations

She collaborates with notable colleagues, including Katsuya Miki and Hiroshi Miyazaki, who contribute to her research and development efforts.

Conclusion

Ayano Suzuki's contributions to biomolecular injection technology highlight her role as a leading inventor in her field. Her innovative approaches promise to enhance the effectiveness of biomolecule delivery systems, paving the way for advancements in medical applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…